IP Library Granted Patent US 9,937,208
Granted Patent B2
US 9,937,208 · App. 13/150,491 · Granted Apr 10, 2018

Modulation of splenocytes in cell therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,937,208
App. No.
13/150,491
Granted
Apr 10, 2018
Kind
B2
Abstract

The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4 + and CD8 + T-cells, increase IL-4 and IL-10, decrease IL-6 and IL-1β, and increase M2:M1 macrophage ratio at the site of injury. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to have these effects. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for achieving these effects.

Claims (10)

1. A method for obtaining cells that have the ability to (1) preserve splenic mass in an injury, (2) increase splenocyte proliferation in the spleen, (3) increase T-regulatory cells; (4) increase one or more of IL-10 and IL-4, or (5) decrease IL-2 and IL-1β, the method comprising assaying cells for said ability by performing one or more of: (1) an assay of splenic mass in an injury, (2) an assay of splenocyte proliferation in the spleen, (3) an assay of T-regulatory cells (4) an assay of IL-10 and IL-4, and (5) an assay of IL-2 and IL-1β, wherein said cells that are assayed are non-embryonic non-germ cells that express one or more of oct4, telomerase rex-1 or rox-1 and/or can differentiate into cell types of at least two of the endodermal, ectodermal, and mesodermal germ layers.

2. The method of claim 1 wherein the cells express telomerase.

3. The method of claim 1 wherein the cells express oct4.

4. The method of claim 1 wherein the cells express oct4 and telomerase.

5. The method of claim 1 wherein the cells can differentiate into cell types of at least two of the endodermal, ectodermal, and mesodermal germ layers.

6. The method of claim 1 wherein the cells can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers.

7. The method of claim 1 wherein the cells express oct4 and telomerase and can differentiate into cell types of at least two of endodermal, ectodermal, and mesodermal germ layers.

8. The method of claim 1 wherein the cells can differentiate into cell types of endodermal, ectodermal, and mesodermal germ layers and express telomerase and oct4.

9. The method of claim 1 wherein the cells are human.

10. The method of claim 1 wherein the cells are derived from bone marrow.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 067606/0139 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2024
From: HEALIOS K.K.
To: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
Reel/Frame 067566/0638 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 1, 2024
From: ABT HOLDING COMPANY; ATHERSYS, INC.; ADVANCED BIOTHERAPEUTICS, INC.; REGENESYS BVBA; REGENESYS, LLC
To: HEALIOS K.K.
Reel/Frame 066435/0775 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2023
From: COX, CHARLES SAMUEL, JR.
To: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 062264/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2011
From: MAYS, ROBERT W.
To: ABT HOLDING COMPANY
Reel/Frame 026825/0748 →